Company Spotlight: Conatus Pharma

Conatus Pharmaceuticals Inc. (CNAT) has returned nearly 54% so far this year compared to a modest 12% rise in the iShares NASDAQ Biotech Index ETF (IBB) during the same period.

from RTT - Biotech http://ift.tt/2pBZRqv
via IFTTT